{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:49:20Z","timestamp":1792090160048,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00520-026-11363-w","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:00:34Z","timestamp":1792087234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune checkpoint inhibitor-related myocarditis, myositis, and myasthenia gravis overlap syndrome: a single-center case series and systematic review"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2211-5696","authenticated-orcid":false,"given":"Jorge","family":"Soriano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4533-2899","authenticated-orcid":false,"given":"Miguel","family":"Mart\u00ednez-Rubi\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0051-918X","authenticated-orcid":false,"given":"Miren","family":"Vicente\u202fElcano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8579-3407","authenticated-orcid":false,"given":"Martina","family":"Pellicer P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5306-8363","authenticated-orcid":false,"given":"Arantxa\u202f","family":"Bergua\u202fde Roque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0696-3856","authenticated-orcid":false,"given":"Sofia","family":"Tanco Mulero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8071-8687","authenticated-orcid":false,"given":"Claudia","family":"Miquel Bosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0471-3230","authenticated-orcid":false,"given":"Ana","family":"Chen-Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2288-5740","authenticated-orcid":false,"given":"Deborah","family":"Mart\u00edn Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7532-3434","authenticated-orcid":false,"given":"Ines","family":"Torras-Vigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2057-5114","authenticated-orcid":false,"given":"Andres","family":"Pellicer-Boiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0053-7938","authenticated-orcid":false,"given":"Mireia","family":"Ble\u202fGimeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4633-9205","authenticated-orcid":false,"given":"Nil","family":"Navarro-Gorro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2774-1290","authenticated-orcid":false,"given":"Laia\u202fCarla","family":"Belarte-Tornero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3409-8857","authenticated-orcid":false,"given":"Laura","family":"Visa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7331-6730","authenticated-orcid":false,"given":"\u00c1lvaro","family":"Taus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6765-5587","authenticated-orcid":false,"given":"Jose\u202fEnrique","family":"Rodriguez Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7304-6857","authenticated-orcid":false,"given":"Alejo","family":"Rodriguez-Vida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8960-7519","authenticated-orcid":false,"given":"Edurne","family":"Arriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6566-3943","authenticated-orcid":false,"given":"Mariona","family":"Llaberia-Torrelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"issue":"10","key":"11363_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70412","volume":"6","author":"H Chen","year":"2025","unstructured":"Chen H, Yang H, Guo L, Sun Q (2025) The role of immune checkpoint inhibitors in cancer therapy: mechanism and therapeutic advances. MedComm (2020) 6(10):e70412. https:\/\/doi.org\/10.1002\/mco2.70412","journal-title":"MedComm (2020)"},{"issue":"2","key":"11363_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"issue":"17","key":"11363_CR3","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36(17):1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"11363_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ajem.2021.03.005","volume":"46","author":"DN Lipe","year":"2021","unstructured":"Lipe DN, Galvis-Carvajal E, Rajha E, Wechsler AH, Gaeta S (2021) Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome. Am J Emerg Med 46:51\u201355. https:\/\/doi.org\/10.1016\/j.ajem.2021.03.005","journal-title":"Am J Emerg Med"},{"issue":"12","key":"11363_CR5","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, Jordan K, Larkin J, ESMO Guidelines Committee (2022) Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33(12):1217\u20131238. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"},{"issue":"16","key":"11363_CR6","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","volume":"96","author":"A Marini","year":"2021","unstructured":"Marini A, Bernardini A, Gigli GL, Valente M, Mu\u00f1iz-Castrillo S, Honnorat J, Vogrig A (2021) Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology 96(16):754\u2013766. https:\/\/doi.org\/10.1212\/WNL.0000000000011795","journal-title":"Neurology"},{"issue":"8","key":"11363_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102586","volume":"19","author":"Y Allenbach","year":"2020","unstructured":"Allenbach Y, Anquetil C, Manouchehri A, Benveniste O, Lambotte O, Lebrun-Vignes B et al (2020) Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmun Rev 19(8):102586. https:\/\/doi.org\/10.1016\/j.autrev.2020.102586","journal-title":"Autoimmun Rev"},{"issue":"10","key":"11363_CR8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30638","volume":"14","author":"AS Zubair","year":"2022","unstructured":"Zubair AS, Roy B, Baehring JM, Nowak RJ (2022) Myasthenia gravis in the setting of immune checkpoint inhibitor therapy: practical considerations and opinion-based approach to acute management. Cureus 14(10):e30638. https:\/\/doi.org\/10.7759\/cureus.30638","journal-title":"Cureus"},{"issue":"1","key":"11363_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","volume":"7","author":"H Safa","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME et al (2019) Immune checkpoint inhibitor-related myasthenia gravis: single-center experience and systematic review of the literature. J Immunother Cancer 7(1):319. https:\/\/doi.org\/10.1186\/s40425-019-0774-y","journal-title":"J Immunother Cancer"},{"issue":"16","key":"11363_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14161794","volume":"14","author":"DN Lipe","year":"2024","unstructured":"Lipe DN, Qdaisat A, Krishnamani PP, Nguyen TD, Chaftari P, El Messiri N et al (2024) Myocarditis, myositis, and myasthenia gravis overlap syndrome associated with immune checkpoint inhibitors: a systematic review. Diagnostics (Basel) 14(16):1794. https:\/\/doi.org\/10.3390\/diagnostics14161794","journal-title":"Diagnostics (Basel)"},{"issue":"13","key":"11363_CR11","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.3390\/cancers17132063","volume":"17","author":"M Furlepa","year":"2025","unstructured":"Furlepa M, Watts I, Carr AS (2025) Management of triple M syndrome: a narrative review of immune checkpoint inhibitor-induced myasthenia gravis, myositis and myocarditis. Cancers (Basel) 17(13):2063. https:\/\/doi.org\/10.3390\/cancers17132063","journal-title":"Cancers (Basel)"},{"issue":"2","key":"11363_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","volume":"140","author":"MP Bonaca","year":"2019","unstructured":"Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, Stewart GC, Choueiri TK, Di Carli M, Allenbach Y et al (2019) Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation 140(2):80\u201391. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034497","journal-title":"Circulation"},{"issue":"7","key":"11363_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002890","volume":"9","author":"AC Guidon","year":"2021","unstructured":"Guidon AC, Burton LB, Chwalisz BK, Hillis J, Schaller TH, Amato AA et al (2021) Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer 9(7):e002890. https:\/\/doi.org\/10.1136\/jitc-2021-002890","journal-title":"J Immunother Cancer"},{"issue":"12","key":"11363_CR14","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/onco.13931","volume":"26","author":"R Pathak","year":"2021","unstructured":"Pathak R, Katel A, Massarelli E, Villaflor VM, Sun V, Salgia R (2021) Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist 26(12):1052\u20131061. https:\/\/doi.org\/10.1002\/onco.13931","journal-title":"Oncologist"},{"key":"11363_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1677984","volume":"16","author":"S Feng","year":"2025","unstructured":"Feng S, Zhao B, Sha S, Bu X, Zhang Z, Liu G, Chen H (2025) Overview of immune checkpoint inhibitor-associated myocarditis mechanisms, diagnostics and treatment. Front Immunol 16:1677984. https:\/\/doi.org\/10.3389\/fimmu.2025.1677984","journal-title":"Front Immunol"},{"issue":"10","key":"11363_CR16","doi-asserted-by":"publisher","first-page":"4876","DOI":"10.4049\/jimmunol.1200389","volume":"188","author":"ML Tarrio","year":"2012","unstructured":"Tarrio ML, Grabie N, Bu DX, Sharpe AH, Lichtman AH (2012) PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol 188(10):4876\u20134884. https:\/\/doi.org\/10.4049\/jimmunol.1200389","journal-title":"J Immunol"},{"issue":"2","key":"11363_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.55563\/clinexprheumatol\/q7mdjs","volume":"41","author":"C Sundarrajan","year":"2023","unstructured":"Sundarrajan C, Bhai S, Dimachkie MM (2023) Immune checkpoint inhibitor-related myositis: from pathophysiology to treatment. Clin Exp Rheumatol 41(2):379\u2013385. https:\/\/doi.org\/10.55563\/clinexprheumatol\/q7mdjs","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"11363_CR18","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1111\/ajco.13442","volume":"17","author":"EYT Wong","year":"2021","unstructured":"Wong EYT, Yong MH, Yong KP, Tan EH, Toh CK, Kanesvaran R, Takano A, Ng QS (2021) Immune checkpoint inhibitor-associated myositis and myasthenia gravis overlap: understanding the diversity in a case series. Asia Pac J Clin Oncol 17(5):e262\u2013e267. https:\/\/doi.org\/10.1111\/ajco.13442","journal-title":"Asia Pac J Clin Oncol"},{"key":"11363_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101192","volume":"50","author":"L Plomp","year":"2025","unstructured":"Plomp L, Chassepot H, Psimaras D, Maisonobe T, Mensi E, Leonard-Louis S et al (2025) Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study. Lancet Reg Health Eur 50:101192. https:\/\/doi.org\/10.1016\/j.lanepe.2024.101192","journal-title":"Lancet Reg Health Eur"},{"issue":"18","key":"11363_CR20","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","volume":"41","author":"L Zhang","year":"2020","unstructured":"Zhang L, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, Thuny F et al (2020) Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J 41(18):1733\u20131743. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa051","journal-title":"Eur Heart J"},{"issue":"3","key":"11363_CR21","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1002\/cam4.5050","volume":"12","author":"J Longinow","year":"2023","unstructured":"Longinow J, Zmaili M, Skoza W, Kondoleon N, Marquardt R, Calabrese C, Funchain P, Moudgil R (2023) Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: a single-center case series. Cancer Med 12(3):2281\u20132289. https:\/\/doi.org\/10.1002\/cam4.5050","journal-title":"Cancer Med"},{"key":"11363_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1661534","volume":"16","author":"MA Satoskar","year":"2025","unstructured":"Satoskar MA, Mansour AG, Wu R, Yang Y, Caldwell MH, Meara AS (2025) An atypical presentation of immune checkpoint inhibitor-associated myositis with normal creatine kinase: a case report. Front Immunol 16:1661534. https:\/\/doi.org\/10.3389\/fimmu.2025.1661534","journal-title":"Front Immunol"},{"issue":"2","key":"11363_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcaa181","volume":"2","author":"S Shelly","year":"2020","unstructured":"Shelly S, Triplett JD, Pinto MV, Milone M, Diehn FE, Zekeridou A, Liewluck T (2020) Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy. Brain Commun 2(2):fcaa181. https:\/\/doi.org\/10.1093\/braincomms\/fcaa181","journal-title":"Brain Commun"},{"key":"11363_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.884776","volume":"13","author":"Y Nakagomi","year":"2022","unstructured":"Nakagomi Y, Tajiri K, Shimada S, Li S, Inoue K, Murakata Y et al (2022) Immune checkpoint inhibitor-related myositis overlapping with myocarditis: an institutional case series and a systematic review of literature. Front Pharmacol 13:884776. https:\/\/doi.org\/10.3389\/fphar.2022.884776","journal-title":"Front Pharmacol"},{"issue":"5","key":"11363_CR25","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jaccao.2022.11.004","volume":"4","author":"A Vasbinder","year":"2022","unstructured":"Vasbinder A, Chen Y, Procureur A, Gradone A, Azam TU, Perry D et al (2022) Biomarker trends, incidence, and outcomes of immune checkpoint inhibitor-induced myocarditis. JACC: CardioOncology 4(5):689\u2013700. https:\/\/doi.org\/10.1016\/j.jaccao.2022.11.004","journal-title":"JACC: CardioOncology"},{"issue":"9","key":"11363_CR26","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/eurheartj\/ehaf315","volume":"47","author":"JR Power","year":"2026","unstructured":"Power JR, Dolladille C, Ozbay B, Procureur A, Ederhy S, Palaskas NL, Lehmann LH et al (2026) Immune checkpoint inhibitor-associated myocarditis: a novel risk score. Eur Heart J 47(9):1050\u20131062. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf315","journal-title":"Eur Heart J"},{"key":"11363_CR27","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3389\/fneur.2020.00634","volume":"11","author":"YT Huang","year":"2020","unstructured":"Huang YT, Chen YP, Lin WC, Su WC, Sun YT (2020) Immune checkpoint inhibitor-induced myasthenia gravis. Front Neurol 11:634. https:\/\/doi.org\/10.3389\/fneur.2020.00634","journal-title":"Front Neurol"},{"issue":"4","key":"11363_CR28","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/cen3.12611","volume":"11","author":"S Suzuki","year":"2020","unstructured":"Suzuki S, Nagane Y, Uzawa A, Imai T, Murai H, Nakahara J, Utsugisawa K (2020) Anti-striational antibodies: expanding their clinical significance. Clin Exp Neuroimmunol 11(4):218\u2013224. https:\/\/doi.org\/10.1111\/cen3.12611","journal-title":"Clin Exp Neuroimmunol"},{"key":"11363_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1455347","volume":"16","author":"X Man","year":"2025","unstructured":"Man X, Wang H, Chen C, Cong X, Sun L, Sun X et al (2025) Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review. Front Immunol 16:1455347. https:\/\/doi.org\/10.3389\/fimmu.2025.1455347","journal-title":"Front Immunol"},{"issue":"24","key":"11363_CR30","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","volume":"141","author":"L Zhang","year":"2020","unstructured":"Zhang L, Zlotoff DA, Awadalla M, Mahmood SS, Nohria A, Hassan MZO et al (2020) Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. Circulation 141(24):2031\u20132034. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044703","journal-title":"Circulation"},{"issue":"5","key":"11363_CR31","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jaccao.2024.07.002","volume":"6","author":"NL Palaskas","year":"2024","unstructured":"Palaskas NL, Siddiqui BA, Deswal A (2024) Steroids in immune checkpoint inhibitor myocarditis. JACC CardioOncol 6(5):800\u2013803. https:\/\/doi.org\/10.1016\/j.jaccao.2024.07.002","journal-title":"JACC CardioOncol"},{"issue":"23","key":"11363_CR32","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","volume":"76","author":"D Barth","year":"2011","unstructured":"Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V (2011) Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 76(23):2017\u20132023. https:\/\/doi.org\/10.1212\/WNL.0b013e31821e5505","journal-title":"Neurology"},{"issue":"3","key":"11363_CR33","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2020","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A et al (2020) International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 96(3):114\u2013122. https:\/\/doi.org\/10.1212\/WNL.0000000000011124","journal-title":"Neurology"},{"issue":"4","key":"11363_CR34","doi-asserted-by":"publisher","first-page":"679","DOI":"10.21037\/cdt-24-114","volume":"14","author":"Y Wang","year":"2024","unstructured":"Wang Y, Li S, Shi H, Guan X, Wei Q, Chen D (2024) Therapeutic agents for steroid-refractory immune checkpoint inhibitor-related myocarditis: a narrative review. Cardiovasc Diagn Ther 14(4):679\u2013697. https:\/\/doi.org\/10.21037\/cdt-24-114","journal-title":"Cardiovasc Diagn Ther"},{"issue":"2","key":"11363_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15020814","volume":"15","author":"A Mauriello","year":"2026","unstructured":"Mauriello A, Correra A, Maratea AC, Cetoretta V, Benfari G, Ilardi F et al (2026) Immune checkpoint inhibitor-associated myocarditis: risk, diagnosis, and clinical impact. J Clin Med 15(2):814. https:\/\/doi.org\/10.3390\/jcm15020814","journal-title":"J Clin Med"},{"issue":"16 Suppl","key":"11363_CR36","doi-asserted-by":"publisher","first-page":"TPS2680","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS2680","volume":"41","author":"KY Reynolds","year":"2023","unstructured":"Reynolds KY, Zlotoff DA, Mooradian M, Zubiri L, Ridker P, Neilan TG (2023) Abatacept for immune checkpoint inhibitor associated myocarditis (ATRIUM): phase 3, investigator-initiated, randomized, placebo-controlled study to evaluate the efficacy and safety of abatacept compared to placebo in hospitalized patients with immune checkpoint inhibitor associated myocarditis. J Clin Oncol 41(16 Suppl):TPS2680. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS2680","journal-title":"J Clin Oncol"},{"issue":"1","key":"11363_CR37","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1186\/s12967-024-05617-6","volume":"22","author":"Q Liu","year":"2024","unstructured":"Liu Q, Liu M, Zou Z, Lin J, Zhang N, Zhao L et al (2024) Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study. J Transl Med 22(1):803. https:\/\/doi.org\/10.1186\/s12967-024-05617-6","journal-title":"J Transl Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11363-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11363-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11363-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:00:35Z","timestamp":1792087235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11363-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["11363"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11363-w","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"15 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This was a retrospective observational study based on anonymized patient data; therefore, formal ethical approval was not required. All data were handled confidentially and processed in accordance with applicable data protection regulations, ensuring that no identifiable patient information was included in the analysis.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.S.\u00a0No\u00a0conflict of interest. M.M.R.\u00a0No\u00a0conflict of interest. M.V.E. has received travel support and speaker fees from Bayer. All conflicts of interest are declared outside the submitted work. M.P.P. No conflict of interest. A.B.R.\u00a0personal\u00a0fees and non-financial support from Pfizer, personal fees from Pierre Fabre and Roche, and non-financial support from Bristol-Myers Squibb, Johnson & Johnson, and Daiichi Sankyo; Lilly and AstraZeneca are also declared. All conflicts of interest are declared outside the submitted work. S.T.M. No\u00a0conflict\u00a0of\u00a0interest. C.M.B. has received congress registration and travel support from\u00a0MSD, Pfizer, Ipsen, Servier, Johnson & Johnson. All conflicts of interest are declared outside the submitted work. A.C-Y.\u00a0No conflict of interest. D.M.R.\u00a0reports personal fees for invited speaker roles for Pfizer,\u00a0AstraZeneca\u00a0and LEO Pharma; and has received congress registration and travel support from Lilly, LEO Pharma, Pierre Fabre, Novartis, MSD,\u00a0Adamed\u00a0Laboratorios and Daiichi-Sankyo. All conflicts of interest are declared outside the\u00a0submitted\u00a0work. I.T.V. No\u00a0conflict\u00a0of\u00a0interest. A.P.B.\u00a0reports personal fees for invited speaker roles for\u00a0AstraZeneca, MSD\u00a0Pfizer,\u00a0AstraZeneca, Abbot, MSD, BMS\u00a0and\u00a0Johnson & Johnson;\u00a0and has received congress registration and travel support from AstraZeneca, Pierre-Fabre, Pfizer, MSD, GSK,\u00a0Merck\u00a0and\u00a0Johnson & Johnson. All conflicts of interest are declared outside the\u00a0submitted\u00a0work. M.B.G. No\u00a0conflict\u00a0of\u00a0interest. N.N.G.\u00a0reports personal fees for invited speaker roles for AstraZeneca, Kyowa Kirin, MSD, Ipsen, Astellas and\u00a0Johnson & Johnson; and has received congress registration and travel support from AstraZeneca, Ipsen, Bayer,\u00a0Johnson & Johnson\u00a0and Boehringer Ingelheim. All conflicts of interest are declared outside the\u00a0submitted\u00a0work. L.C.B.T. No\u00a0conflict\u00a0of\u00a0interest. L.V.\u00a0reports personal fees for invited speaker roles and non-financial\u00a0support from\u00a0from\u00a0BMS, Astra\u00a0Zeneca,\u00a0Beone\u00a0Astellas;\u00a0and travel support from\u00a0Beone, AstraZeneca, Astellas. A.T.\u00a0reports personal fees\u00a0for invited speaker roles\u00a0and non-financial\u00a0support\u00a0from\u00a0GSK, Takeda, Sanofi, Roche, BMS, MSD, AstraZeneca, Pfizer, and Eisai; and travel support from GSK. J.E.R.M. No conflict of interest. A.R-V.\u00a0reports serving in an advisory role for Pfizer, Bristol Myers Squibb, Merck Serono, MSD, Astellas,\u00a0Johnson & Zeneca, Bayer, Novartis and Ipsen; receiving honoraria or travel expenses from Pfizer, MSD, Astellas, Merck Serono, Bristol Myers Squibb,\u00a0Johnson & Zeneca, Bayer, Novartis and Ipsen. E.A.\u00a0reports grants, personal fees, and non-financial support from Roche, personal fees, and non-financial support from BMS, personal fees and non-financial support from MSD, personal fees from AstraZeneca, grants and personal fees from Pfizer, personal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from Lilly, as well as personal fees from Takeda. All conflicts of interest are declared outside the submitted work. M.L.T. No conflict of interest.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1108"}}